Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug News Perspect. 2009 Apr;22(3):146-50. doi: 10.1358/dnp.2009.22.3.1354124.

Syk kinase inhibitors in allergic diseases.

Author information

  • 1Respiratory CEDD, GlaxoSmithKline Medicines Research Centre, Stevenage, Herts SG1 2NY, UK. jane.c.denyer@gsk.com

Abstract

Recent advances in the understanding of allergic mechanisms have highlighted the role of immunoglobulin E (IgE) signaling in the mast cell. One of the most important kinases in the IgE signaling pathway is spleen tyrosine kinase (Syk) which has a critical function early in the signaling cascade following binding of allergen to receptor bound IgE on the mast cell. A number of Syk inhibitors have now been developed which have been shown to effectively inhibit IgE-driven mast cell degranulation and release of inflammatory cytokines in vitro and inhibit allergic responses in a variety of in vivo models. In humans, allergen-driven symptoms were reduced in allergic rhinitic patients exposed to tree pollen in an outdoor environment following intranasal dosing of the Syk inhibitor R-112. Syk therefore represents a promising target for therapeutic intervention in allergic diseases.

Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

PMID:
19440557
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Write to the Help Desk